Journal of Clinical Oncology
Articles in this Issue
A phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib (TYRA-300) in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302).
TPS886 Background: Intermediate risk non-muscle invasive bladder cancer (IR NMIBC) is characterized by a high prevalence o...
Multi-omic remodeling of urine-exposed ileal mucosa after ileocystoplasty.
856 Background: Ileal segments are widely used for urinary diversion, yet long-term dysfunction (increased residual urine...
Non-invasive prostate cancer subtyping using 5hmC-sequencing of cell-free DNA.
242 Background: Optimizing treatment for metastatic castration-resistant prostate cancer (mCRPC) requires knowledge of dif...
Effects of obesity on biphasic immune remodeling of CD45⁺ circulating cells during androgen deprivation therapy in prostate cancer.
216 Background: Androgen-deprivation therapy (ADT) is essential for advanced prostate cancer but linked to early inflammat...
Survival outcomes with lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer patient according to baseline tumor characteristics.
35 Background: To investigate cancer-control outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients...
Trial design and objectives for prostate cancer: Recommendations from the Prostate Cancer Clinical Trials Working Group 4 (PCWG4).
162 Background: Clinical trial conduct in advanced prostate cancer has changed dramatically with the continued development...
A clinical, evidence-based risk estimator for individualizing benefit and response in oligometastatic prostate cancer (CEREBRO): A tool from the X-Met collaboration.
160 Background: To our knowledge, no tools are available to guide care in oligometastatic prostate cancer (omPC). Here, we...
Real-world urinary detection of FGFR alterations to guide FGFR inhibitor therapy in bladder cancer.
848 Background: FGFR inhibitors have emerged as a promising therapeutic option for urothelial bladder...
Utility of circulating tumor DNA in patients with renal cell carcinoma at increased risk of recurrence after resection.
519 Background: Despite approval of adjuvant pembrolizumab for high-risk renal cell carcinoma (RCC), risk of disease recur...
Membranous Nectin-4 expression to predict enfortumab vedotin response in metastatic urothelial carcinoma.
854 Background: Enfortumab vedotin (EV) is a standard of care for metastatic urothelial carcinoma (mUC), yet robust predic...
Patterns of neoadjuvant chemotherapy (NAC) use in stage II-III bladder cancer: A California Cancer Registry (CCR) analysis.
647 Background: NAC followed by radical cystectomy (RC) improves survival compared to RC alone in patients with muscle inv...
Parallel liquid biopsy analysis of miR-371a-3p and cell-free DNA in testicular germ cell tumors.
614 Background: miR-371a-3p has emerged as a novel biomarker in testicular germ cell tumors (TGCTs), showing strong potent...
Predictors of early termination in phase 2–3 genitourinary oncology trials: A two-decade analysis of clinicaltrials.gov.
331 Background: Early termination of clinical trials delays progress and wastes resources. Predictors of such discontinuat...
Association between preoperative glycemic control and outcomes after radical prostatectomy.
345 Background: Elevated hemoglobin A1c (A1c) levels are often thought to contribute to adverse perioperative outcomes in...
A composite biomarker approach to withhold neoadjuvant chemotherapy in select muscle-invasive bladder cancer patients.
841 Background: Neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) is recommended for muscle-invasive bladder...
Phase 1/2 study of an anti-PD-L1/IL-15 variant fusion protein (SIM0237) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC).
764 Background: Treatment options for BCG-unresponsive (UR) NMIBC are limited. Anti-PD-1 monotherapy and IL-15 agonist in...
Early relative dose intensity to predict survival outcomes in patients treated with enfortumab vedotin for metastatic urothelial carcinoma.
683 Background: Enfortumab vedotin (EV) is a standard therapy for metastatic urothelial carcinoma (mUC) after platinum-bas...
Overall survival (OS) in elderly, frail, or high comorbidity veterans receiving androgen receptor pathway inhibitors (ARPIs) with androgen-deprivation therapy (ADT) vs ADT alone for de novo metastatic castration-sensitive prostate cancer (mCSPC).
103 Background: Clinical trials and real-world analyses have shown that combining an ARPI (abiraterone, apalutamide, darol...
Stockholm3-MRI population-based screening: Two-year outcomes comparing Stockholm3 and PSA.
314 Background: Diagnostic accuracy estimates for prostate cancer tests are often biased when biopsy verification depends...
Association of prior 5-α-reductase inhibitor exposure with ICI benefit in metastatic RCC: Multicentre cohort with single-cell immune profiling.
521 Background: Immune checkpoint inhibitors (ICIs) improve survival in metastatic renal cell carcinoma (mRCC), yet respon...
OMAHA-004: Phase 3 trial of CYP11A1 inhibitor opevesostat versus androgen receptor pathway inhibitor (ARPI) switch in participants with metastatic castration-resistant prostate cancer (mCRPC) after a prior ARPI.
TPS299 Background: Opevesostat (MK-5684; ODM-208) is an oral, nonsteroidal inhibitor of cytochrome P450 11A1 (CYP11A1), a...
Real-world darolutamide safety and effectiveness in nonmetastatic castration-resistant prostate cancer (nmCRPC) by lipid-modifying agent use: Post hoc analyses of DAROL interim analysis 4 (IA4).
99 Background: Darolutamide is approved for nmCRPC based on significant metastasis-free survival (MFS) and overall surviva...
Homologous recombination deficiency signature (HRDsig) in adenocarcinoma of the bladder (ACB): Implications for PARP inhibitor (PARPi) treatment.
853 Background: Pure and predominant non-urachal adenocarcinoma histologies in primary bladder carcinomas are uncommon. Gi...
Implementing evidence-based first-line therapy for metastatic urothelial carcinoma: A quality improvement initiative in community oncology.
664 Background: First-line (1L) novel combination regimens have transformed outcomes for pts with locally advanced or meta...
Clinical characteristics and survival outcomes in veterans receiving radium-223 for metastatic castration-resistant prostate cancer.
112 Background: Radium-223 is an alpha-emitting radiopharmaceutical that selectively targets bone metastases while minimiz...